Alpine's Pipeline

We have a diverse pipeline of multi-targeted therapies in development for both autoimmune/inflammatory disease and immuno-oncology.

Wholly Owned Programs

INFLAMMATORY DISEASES

ALPN-303

Dual B Cell Cytokine (BAFF/APRIL) Antagonist

PRECLINICAL

COMPLETED

PHASE 1

IN PROGRESS

PHASE 2

NOT STARTED

PHASE 3

NOT STARTED

SLE and other B cell-mediated diseases

50%

Details

Commmercial Rights:

Alpine Immune Sciences logo

ALPN-303 is a dual B cell cytokine antagonist being developed for multiple autoimmune and/or inflammatory diseases.

We reported data from the ongoing RUBY-1 study, a phase 1 study of ALPN-303 in healthy volunteers (NCT05034484) in September 2022. This study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALPN-303.

Learn More

Partnered Programs

acazicolcept (ALPN-101)

Dual CD28/ICOS Antagonist

PRECLINICAL

COMPLETED

PHASE 1

COMPLETED

PHASE 2

IN PROGRESS

PHASE 3

NOT STARTED

Systemic lupus erythematosus

70%
Synergy logo

Details

Partners:

AbbVie logo

Acazicolcept is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways. The molecule is being developed for treatment of severe inflammatory diseases.

We are currently enrolling Synergy, a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus (NCT04835441). This randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of acazicolcept.

Learn More

Discovery Collaboration

Immunology

PRECLINICAL

IN PROGRESS

PHASE 1

NOT STARTED

PHASE 2

NOT STARTED

PHASE 3

NOT STARTED

Undisclosed

20%
Horizon logo

Next Generation TCR T-cell Therapies

PRECLINICAL

IN PROGRESS

PHASE 1

NOT STARTED

PHASE 2

NOT STARTED

PHASE 3

NOT STARTED

Undisclosed

20%
Adaptimmune logo

For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filingscorporate presentations, and scientific publications.

Join us in the discovery and development of next-generation immunotherapies.

Current job openingsLearn more about Alpine